All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

The application of advanced diagnostic and screening techniques led to the increased detection of early staged non-small cell lung cancers (NSCLC) and improved cures using standard surgery \[[@pone.0146195.ref001]\]. The 5-year survival after resection of localized NSCLC approaches a modest 50% despite improved surgical techniques and advanced adjuvant therapy \[[@pone.0146195.ref002], [@pone.0146195.ref003]\]. No prognostic factor, except stage and performance status, was definitively established in NSCLC. Accurate markers would be invaluable to stratify patients for adjuvant therapy and predict outcomes.

^18^F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) is the standard modality for staging, treatment response monitoring and prognosis prediction for a variety of tumors, including NSCLC \[[@pone.0146195.ref004], [@pone.0146195.ref005]\]. Standardized uptake value (SUV) is a semi-quantitative determination of the normalized concentration of radioactivity, and maximum SUV (SUV~max~) is the most widely applied parameter in clinical practice \[[@pone.0146195.ref006]\]. Volumetric parameters, including metabolic tumor volume (MTV) and total lesion glycolysis (TLG), were also used recently to reflect disease burden and tumor aggressiveness in NSCLC \[[@pone.0146195.ref004], [@pone.0146195.ref007]\]. Several recent systematic reviews and meta-analyses \[[@pone.0146195.ref008]--[@pone.0146195.ref010]\] found that SUV was negatively correlated with prognosis in heterogeneous groups of NSCLC patients. Im et al. \[[@pone.0146195.ref011]\] reported significant prognostic values of MTV and TLG on survival in NSCLC patients. However, the quality of existing studies has not been systematically assessed, and their clinical features have not been fully assessed to further evaluate the potential association between SUV or volumetric parameters and prognosis in surgical NSCLC.

Therefore, we performed a meta-analysis to identify, appraise, and synthesize results from published studies that examined the prognostic value of SUV~max~, MTV and TLG on disease-free survival (DFS) and overall survival (OS) in surgical NSCLC patients.

Materials and Methods {#sec006}
=====================

Search Strategy and Eligible Criteria {#sec007}
-------------------------------------

MEDLINE, EMBASE and Cochrane Library were searched and updated through August 1, 2015. The following terms were used: "non-small cell lung cancer" OR "NSCLC" OR "carcinoma, non-small cell lung" AND "^18^F-FDG" OR "fluorodeoxyglucose" OR "PET" OR "positron emission tomography" AND "survival" OR "local control" OR "prognostic" OR "outcome" OR "predict" AND "surgery" OR "resect" OR "operation". Reviews, case studies, conference abstracts and editorials were excluded.

Two authors independently searched articles and performed an initial screening of identified titles and abstracts. Articles were further reviewed if they reported the prognosis of surgically resected NSCLC patients with pre-operative ^18^F-FDG PET/CT imaging from original data. Full-text articles were used for the second screening. The following inclusion criteria for the meta-analysis were used: (1) prospective or retrospective studies investigating the correlation of FDG uptake with DFS, recurrence-free survival (RFS), and/or OS; (2) pathological stage I-IIIA NSCLC patients who received diagnostic ^18^F-FDG PET/CT scanning before treatments; (3) treated with surgery alone or adjuvant therapy; (4) survival data assessed in detail; and (5) surgical procedures included either full anatomical resections or limited lung resection regardless of whether they were performed via open thoracotomy or video-assisted thoracic surgery. A consensus resolved any discrepancies.

Studies that included patients with small cell lung cancer (SCLC) were eligible if more than 95% of patients had NSCLC. Patients with an advanced stage (IIIB-IV) also accounted for less than 5% of the included studies. Data were partially extracted when only certain sub-group analyses met our inclusion criteria. Studies that included patients who received neoadjuvant therapy were excluded. Only the most recent or complete report was included when the survival results of the same patient population were reported more than once.

Data Extraction {#sec008}
---------------

Data extraction was conducted in agreement with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance ([S1 PRISMA Checklist](#pone.0146195.s001){ref-type="supplementary-material"}) \[[@pone.0146195.ref012]\]. Two investigators independently extracted information, including the first author, publication year, country, study design, sample size, stage, treatment, and survival endpoints. The primary endpoint was DFS, which was measured from the defined starting point in each study to the date of recurrence or first progression. OS was taken as the secondary endpoint and defined as the time from the starting point applied in each study to death.

Study Quality Control {#sec009}
---------------------

Three investigators reviewed and scored each article independently using a quality scale ([S1 File](#pone.0146195.s002){ref-type="supplementary-material"}). Quality assessment included four modified parts based on similar studies: scientific design, the generalizability of the results, data analyses, and PET reports \[[@pone.0146195.ref013]--[@pone.0146195.ref015]\]. Five items were observed in each part. A point value of 0, 1, or 2 was scored to each item. A consensus was obtained of all investigators present, which ensured the objectivity of the scores and correct interpretation. Final scores are expressed as percentages, and higher values reflect a greater consistence with quality assessment standards. Any article with a final score \< 60% was excluded.

Statistical Analysis {#sec010}
--------------------

Review Manager statistical software (RevMan, version 5.3) was used. The impact of SUV~max~, MTV and TLG on DFS and OS was measured using hazard ratios (HRs). Survival data were extracted using the methodology suggested by Tierney et al. \[[@pone.0146195.ref016]\]. Cut-off values of SUV~max~, MTV and TLG and the delineation thresholds applied to MTV and TLG were determined based on the definition applied in each individual study. Unadjusted and adjusted values were extracted for risk measurements. We extracted the HR estimate and 95% confidence intervals (CIs) directly from each study when provided by the authors. *P* values of the log-rank test, number analyzed in each group, and the number of events were extracted to estimate the univariate HR indirectly. Correlations between the quality scores and the number of patients were measured using the Spearman's rank correlation coefficient.

Heterogeneity was evaluated using Cochrane's Q test and *I*^*2*^ \[[@pone.0146195.ref017]\]. *P*\<0.05 in Q test was considered significant heterogeneity. An *I*^*2*^ value of 0% indicates no heterogeneity, a value less than 25% indicates low heterogeneity, a value of 25.1--50% indicates moderate heterogeneity, and a value greater than 50% indicates substantial heterogeneity \[[@pone.0146195.ref018]\]. A fixed effect model was used to calculate the pooled HRs when no, low or moderate heterogeneity was observed. A random effects model was applied when substantial or significant heterogeneity was observed. An HR greater than 1 implied worse survival outcome for patients with high SUV~max~, MTV or TLG, but an HR less than 1 implied a survival benefit for patients with high SUV~max~, MTV or TLG. Sub-group analyses were performed based on histological subtypes, pathological stage, surgery only and cut-off values.

The possibility of publication bias was estimated using visual inspection of a funnel plot. Begg's test was performed for meta-analysis that included more than 10 studies \[[@pone.0146195.ref019], [@pone.0146195.ref020]\]. We also performed non-parametric "trim and fill" procedures to further estimate the potential influence of publication bias \[[@pone.0146195.ref021], [@pone.0146195.ref022]\]. This procedure calculates a new pooled HR that incorporates hypothetical missing studies.

Results {#sec011}
=======

Study Characteristics and Qualitative Assessment {#sec012}
------------------------------------------------

Thirty-six eligible studies were included in the meta-analysis \[[@pone.0146195.ref023]--[@pone.0146195.ref058]\] ([Fig 1](#pone.0146195.g001){ref-type="fig"}, Tables [1](#pone.0146195.t001){ref-type="table"} and [2](#pone.0146195.t002){ref-type="table"}). Only two studies \[[@pone.0146195.ref031], [@pone.0146195.ref037]\] were prospectively designed. The studies were published between 2000 and 2015, and the sample size varied from 49 to 530 subjects (median 102). Only 5 SCLC \[[@pone.0146195.ref040], [@pone.0146195.ref051]\] patients were mixed into the analysis of 5807 patients. Four studies lacked raw data of stage \[[@pone.0146195.ref023], [@pone.0146195.ref029], [@pone.0146195.ref040], [@pone.0146195.ref049]\], but the distribution of stages I, II, III and IV were 80.4%, 14.2%, 4.5% (2.7% IIIA, 0.9% IIIB, and 0.9% stage III) and 0.9%, respectively. [Table 1](#pone.0146195.t001){ref-type="table"} lists PET/CT scans and models. The dose of FDG injected varied from 150 to 666 MBq based on different individual scanning protocols. The time duration before scanning was 40--60 minutes in 28 studies, 81 minutes in 1 study, 90 minutes in 1 study and not reported in 6 studies. SUV~max~ was measured in 34 studies \[[@pone.0146195.ref023]--[@pone.0146195.ref025], [@pone.0146195.ref028]--[@pone.0146195.ref058]\], which normalized values by body weight. MTV was measured in 7 studies \[[@pone.0146195.ref024], [@pone.0146195.ref026]--[@pone.0146195.ref029], [@pone.0146195.ref052], [@pone.0146195.ref053]\], and TLG was measured in 7 studies \[[@pone.0146195.ref024], [@pone.0146195.ref026], [@pone.0146195.ref027], [@pone.0146195.ref029], [@pone.0146195.ref052], [@pone.0146195.ref053], [@pone.0146195.ref056]\]. A fixed SUV of 2.5 \[[@pone.0146195.ref027], [@pone.0146195.ref028], [@pone.0146195.ref052], [@pone.0146195.ref056]\], the gradient segmentation method \[[@pone.0146195.ref029]\], a 50% of SUV~max~ \[[@pone.0146195.ref024]\], a 42% of SUV~max~ \[[@pone.0146195.ref053]\], and mediastinal background SUV~mean~ plus 2 standard deviations \[[@pone.0146195.ref026]\] were adapted to segment volumes of interest. A minimum *P* value, receiver operating characteristics (ROCs), and median value were applied in most studies to determine cut-off values. Median cut-off points were 5.90 (2.4 to 20) for SUV~max~. The cut-off values of MTV were between 2.95 and 37.34 cm^3^ (median 11.197 for OS and 10.29 for DFS), and TLG values ranged from 9.61 to 407.48 (median 26.739 for OS and 29.221 for DFS).

![Flowchart of Study Selection.](pone.0146195.g001){#pone.0146195.g001}

10.1371/journal.pone.0146195.t001

###### Studies Included in Meta-Analysis.

![](pone.0146195.t001){#pone.0146195.t001g}

  Study                                             Year   Country       Study design   No. of patients   TNM staging   Treatment                      Endpoints            PET scanners                                                                      PET parameters      Tumor delineation (thresholds)                                Determination of cut-off values   Cut-off values                  
  ------------------------------------------------- ------ ------------- -------------- ----------------- ------------- ------------------------------ -------------------- --------------------------------------------------------------------------------- ------------------- ------------------------------------------------------------- --------------------------------- ---------------- -------------- ---------------
  Cistaro et al. \[[@pone.0146195.ref023]\]         2013   Italy         R              49                I-II          Surgery                        DFS                  Discovery ST, GE                                                                  SUV~max~                                                                          Minimum P value method            9.0                             
  Melloni et al. \[[@pone.0146195.ref024]\]         2013   Italy         R              99                I             Surgery                        DFS                  Discovery STE or Discovery 690, GE; GEMINI-GXL, Philips                           SUV~max~ /MTV/TLG   50%SUV~max~                                                   Median                            2.73             2.95           9.61
  Ohtaka et al. \[[@pone.0146195.ref025]\]          2013   Japan         R              191               I-IIIA        Surgery                        OS/DFS               ECAT EXACT HR+, Siemens                                                           SUV~max~                                                                          Median                            2.4                             
  Hyun et al. \[[@pone.0146195.ref026]\]            2013   Korea         R              529               I-II          Surgery ± adjuvant CT/RT/CRT   OS/DFS               Discovery LS, GE                                                                  MTV/TLG             Mediastinal background SUV~mean~ plus 2 standard deviations   ROC curve                                          16             70
  Kim et al. \[[@pone.0146195.ref027]\]             2012   Korea         R              91                I-IIIA        Surgery ± adjuvant CT          OS/RFS               Gemini, Philips; Biograph40, Siemens                                              MTV/TLG             SUV2.5                                                        ROC curve                                          11.613/9.598   13.797/18.762
  Lin et al. \[[@pone.0146195.ref028]\]             2012   Taiwan        R              60                I             Surgery                        DFS                  Discovery STE, GE                                                                 SUV~max~/MTV        SUV2.5                                                        Median                            2.5              9.8            
  Zhang et al. \[[@pone.0146195.ref029]\]           2013   China         R              59                I-IV          Surgery                        OS                   Reveal HD, CTI                                                                    SUV~max~ /MTV/TLG   Gradient tumor segmentation                                   ROC curve                         11.59            37.34          407.48
  Agarwal et al. \[[@pone.0146195.ref030]\]         2010   USA           R              363               I-II          Surgery                        OS                   Discovery DST or Advance, GE                                                      SUV~max~                                                                          Median                            5.9                             
  Dooms et al. \[[@pone.0146195.ref031]\]           2009   Belgium       P              91                I-II          Surgery                        OS                   931/08/12 or ECAT EXACT 922, CTI-Siemens                                          SUV~max~                                                                          Median                            NR                              
  Goodgame et al. \[[@pone.0146195.ref032]\]        2008   USA           R              136               I             Surgery                        Recurrence rate/OS   ECAT EXACT or Biograph LSO Duo hybrid PET/CT, Siemens; ADAC CPET-Plus, Phillips   SUV~max~                                                                          Median                            5.5                             
  Hanin et al. \[[@pone.0146195.ref033]\]           2008   Belgium       R              96                I-II          Surgery                        OS/DFS               ECAT HR+, Siemens                                                                 SUV~max~                                                                          Median                            7.8                             
  Kim et al. \[[@pone.0146195.ref034]\]             2011   Korea         R              76                I-II          Surgery                        OS/DFS               Gemini, Philips                                                                   SUV~max~                                                                          ROC curve                         6.7/5.9                         
  Nair et al. \[[@pone.0146195.ref035]\]            2010   USA           R              75                IA            Surgery                        OS                   CTI                                                                               SUV~max~                                                                          Minimum P value method            5                               
  Um et al. \[[@pone.0146195.ref036]\]              2009   Korea         R              145               I             Surgery                        DFS                  Discovery LS, GE                                                                  SUV~max~                                                                          ROC curve                         13.1                            
  Vesselle et al. \[[@pone.0146195.ref037]\]        2007   USA           P              103               I-III         Surgery                        OS/DFS               PET Advance, GE                                                                   SUV~max~                                                                          Minimum P value method            7                               
  Zhang et al. \[[@pone.0146195.ref038]\]           2007   China         R              82                I-III         Surgery ± adjuvant CT          OS/DFS               Discovery LS, GE                                                                  SUV~max~                                                                          Median                            11                              
  Bille et al. \[[@pone.0146195.ref039]\]           2013   UK            R              404               I-IV          Surgery ± adjuvant CT          OS                   Discovery ST, GE                                                                  SUV~max~                                                                          Median                            8.6                             
  Dhital et al. \[[@pone.0146195.ref040]\]          2000   UK            R              77                I-IIIA        Surgery                        OS                   ECAT 951/31R, Siemens                                                             SUV~max~                                                                          Minimum P value method            20                              
  Higashi et al. \[[@pone.0146195.ref041]\]         2002   Japan         R              57                I-III         Surgery                        OS/DFS               Headtome IV, Shimazu                                                              SUV~max~                                                                          Minimum P value method            5                               
  Kim et al. \[[@pone.0146195.ref042]\]             2009   Korea         R              107               I             Surgery                        DFS                  Allegro, Philips                                                                  SUV~max~                                                                          Median                            2.4                             
  Ohtsuka et al. \[[@pone.0146195.ref043]\]         2006   Japan         R              98                I             Surgery                        DFS                  NR                                                                                SUV~max~                                                                          ROC curve                         3.3                             
  Stiles et al. \[[@pone.0146195.ref044]\]          2013   USA           R              530               I-IIIA        Surgery                        DFS                  NR                                                                                SUV~max~                                                                          Median                            4.8                             
  Tomita et al. \[[@pone.0146195.ref045]\]          2012   Japan         R              197               I-III         Surgery                        OS                   Siemens                                                                           SUV~max~                                                                          Median                            6.6                             
  Tsutani et al. \[[@pone.0146195.ref046]\]         2011   Japan         R              176               I-III         Surgery                        DFS                  Discovery ST16, GE                                                                SUV~max~                                                                          ROC curve                         3.7/6.95                        
  van Baardwijk et al. \[[@pone.0146195.ref047]\]   2007   Netherlands   R              102               I-III         Surgery                        OS                   931/08/12 or ECAT EXACT 922, CTI-Siemens                                          SUV~max~                                                                          Minimum P value method            8/11                            
  Downey et al. \[[@pone.0146195.ref048]\]          2007   UK            R              487               I-IV          Surgery                        OS                   NR                                                                                SUV~max~                                                                          Median                            5.3                             
  Koo et al. \[[@pone.0146195.ref049]\]             2011   Korea         R              75                I-II          Surgery                        DFS                  Gemini, Philips                                                                   SUV~max~                                                                          ROC curve                         4.5                             
  Pelosi et al. \[[@pone.0146195.ref050]\]          2011   Italy         R              153               I-IV          Surgery ± adjuvant CT          OS/DFS               Discovery ST, GE                                                                  SUV~max~                                                                          Minimum P value method            9                               
  Shiono et al. \[[@pone.0146195.ref051]\]          2011   Japan         R              201               I             Surgery ± adjuvant CT          DFS                  Discovery LS, GE                                                                  SUV~max~                                                                          ROC curve                         4.7                             
  Kim et al. \[[@pone.0146195.ref052]\]             2014   Korea         R              102               I-II          Surgery                        DFS                  Reveal RT-HiREZ, CTI; Discovery STE, GE                                           SUV~max~ /MTV/TLG   SUV2.5                                                        ROC curve                         6.90             10.78          39.68
  Domachevsky et al \[[@pone.0146195.ref053]\]      2015   Israel        R              181               I-II          Surgery                        OS                   Discovery STE, GE                                                                 SUV~max~ /MTV/TLG   42%SUV~max~                                                   Median                            8.2              NR             NR
  Ko et al \[[@pone.0146195.ref054]\]               2015   Taiwan        R              145               IA            Surgery                        RFS                  Biograph, Siemens                                                                 SUV~max~                                                                          ROC curve                         2.5                             
  Motono et al \[[@pone.0146195.ref055]\]           2014   Japan         R              58                I-IIIA        Surgery                        DFS                  Headtome IV, Shimazu                                                              SUV~max~                                                                          NR                                NR                              
  Park et al \[[@pone.0146195.ref056]\]             2015   Korea         R              248               IA            Surgery                        OS                   Discovery 600, GE; Biograph TruePoint 40, Siemens                                 SUV~max~ /TLG       SUV2.5                                                        Maximally selected rank           3.7                             13.76
  Shimizu et al \[[@pone.0146195.ref057]\]          2014   Japan         R              84                I-III         Surgery                        DFS                  Discovery ST, GE                                                                  SUV~max~                                                                          ROC curve                         3.95/9.7                        
  Yoo et al \[[@pone.0146195.ref058]\]              2014   Korea         R              80                I-IIA         Surgery                        DFS                  Biographs; Siemens                                                                SUV~max~                                                                          Minimum P value method            4                               

**Abbreviations:** T: tumor; N: lymph node; M: metastasis; PET: positron emission tomography; SUV: standardized uptake value; MTV: metabolic tumor volume; TLG: total lesion glycolysis; R: retrospective; P: prospective; DFS: disease-free survival; OS: overall survival; SUV~max~: maximal standardized uptake value; CT: chemotherapy; RT: radiotherapy; CRT: chemoradiotherapy; SUV~mean~: mean standardized uptake value; ROC: receiver operating characteristic; RFS: recurrence-free survival; NR: not reported.

10.1371/journal.pone.0146195.t002

###### Clinical Characteristics of Included Studies.

![](pone.0146195.t002){#pone.0146195.t002g}

  Study Criteria                                     No. of Studies
  -------------------------------------------------- ----------------
  Study design                                       
      Prospective design                             2
      Retrospective design                           34
  Histology                                          
      Adenocarcinoma only                            4
      NSCLC                                          30
      NSCLC and SCLC                                 2
  Treatment                                          
      Surgery only                                   30
      Surgery ± adjuvant chemotherapy                5
      Surgery ± adjuvant chemotherapy/radiotherapy   1
  Prognostic parameters                              
      SUV~max~                                       34
      MTV                                            7
      TLG                                            7
  Determination of cut-off values                    
      Minimum P value                                8
      Receiver operating characteristics curve       12
      Median value                                   14
      Others                                         2
  HR reported                                        
      Adjusted                                       25
      Unadjusted                                     35
  Multivariate analysis (with adjustment for)        
      Tumor stage                                    14
      Stage                                          11
      Age                                            9
      Gender                                         6
      Histology                                      6
      Lymph node status                              5
      Differentiation                                5
      Carcino-embryonic antigen level                4
  Follow-up schedule                                 
      Well-planned and described in detail           11
      Well-planned but not described in detail       5
      Not indicated                                  20

**Abbreviations:** NSCLC: non-small cell lung cancer; SCLC: small cell lung cancer; SUV~max~: maximal standardized uptake value; MTV: metabolic tumor volume; TLG: total lesion glycolysis; DFS: disease-free survival; OS: overall survival; HR: hazard ratio; PET/CT: positron emission tomography/computed tomography.

Adjusted HRs were determined for 25 studies. Most risk measures were adjusted for tumor size or T stage, stage, age, gender and histology, and other studies were adjusted for lymph node status, differentiation and CEA level.

Twenty-seven studies published complete resection rates as 100%, while the remaining studies did not report rates. Average (mean or median) follow-up duration was given in 29 studies and ranged from 16.6 to 64 months (median 32.0 months). The follow-up design was reported in detail in 11 studies, but it was not indicated in 20 studies.

Attempts to contact the authors to obtain missing information of methodological quality were made when necessary, and the mean quality score was 77.5% (70.0% to 87.5%). Spearman's correlation coefficient was 0.326 between the quality score and the number of patients (*P* = 0.36).

Primary Outcome: DFS {#sec013}
--------------------

Unadjusted analysis of SUV~max~ and DFS (2845 patients) revealed a combined HR of 2.74 (95%CI: 2.33--3.24, *P* = 0.07, *I*^*2*^ = 32%) ([Fig 2A](#pone.0146195.g002){ref-type="fig"}). The funnel plots for publication bias exhibited significant asymmetry with statistical significance (Begg's test, *z* = 3.59, *P*\<0.001). The pooled HR was 2.37 (95% CI: 2.03--2.75) after the trim and fill analysis ([Fig 3A](#pone.0146195.g003){ref-type="fig"}). Sensitively analysis was further conducted with significant heterogeneity (*I*^*2*^ = 72%, *P*\<0.00001, HR 2.43, 95%CI: 1.76--3.36) for multivariate analysis of SUV~max~ and DFS (2279 patients) ([Fig 2B](#pone.0146195.g002){ref-type="fig"}) to estimate the effect of each study on the pooled HR by omitting one study at a time. Three studies \[[@pone.0146195.ref034], [@pone.0146195.ref044], [@pone.0146195.ref055]\] were omitted, and an HR of 3.24 (2.43--4.33) using a fixed-model was obtained with a decreased I^2^ of 38% and a P value of 0.07 in the Q test. The Begg's test was statistically significant (*z* = 2.23, *P* = 0.026). The pooled HR was 1.77 (95% CI: 1.29--2.43) after the trim and fill analysis ([Fig 3B](#pone.0146195.g003){ref-type="fig"}).

![Forest plots of HR for recurrence with SUV~max~ (A, unadjusted; B, adjusted), MTV (C, unadjusted; D, adjusted) and TLG (E, unadjusted; F, adjusted).\
The Chi^2^ test is a measurement of heterogeneity. *P*\<0.05 indicates significant heterogeneity. Squares = individual study point estimates. Horizontal lines = 95% CIs. Rhombus = summarized estimate and its 95% CI. Fixed: fixed effect model. Random: random effect model.](pone.0146195.g002){#pone.0146195.g002}

![Funnel plots without (left column) and with (right column) trim and fill.\
The pseudo 95% confidence interval (CI) is computed as part of the analysis that produced the funnel plot and corresponds to the expected 95% CI for a given standard error (SE). HR indicates hazard ratio.](pone.0146195.g003){#pone.0146195.g003}

Five studies (881 patients) indicated that a larger MTV predicted worse local control using univariate analysis with a pooled HR of 2.27 (95% CI: 1.77--2.90, *P* = 0.16, *I*^*2*^ = 39%) ([Fig 2C](#pone.0146195.g002){ref-type="fig"}). Three studies obtained the same result \[[@pone.0146195.ref026], [@pone.0146195.ref027], [@pone.0146195.ref052]\] for multivariate analysis, and 1 study reported undetermined results \[[@pone.0146195.ref028]\]. The combined HR of all 4 studies (782 patients) was 2.49 (95% CI: 1.23--5.04, *P* = 0.04, *I*^*2*^ = 63%) ([Fig 2D](#pone.0146195.g002){ref-type="fig"}). High TLG was associated with poor local control in 4 studies (821 patients) using univariate analysis with a combined HR of 2.46 (95% CI: 1.91--3.17, *P* = 0.39, *I*^*2*^ = 1%) ([Fig 2E](#pone.0146195.g002){ref-type="fig"}). Multivariate analysis with 3 studies (730 patients) revealed a combined HR of 2.97 (95%CI: 1.68--5.28, *P* = 0.09, *I*^*2*^ = 59%) ([Fig 2F](#pone.0146195.g002){ref-type="fig"}).

Secondary Outcome: OS {#sec014}
---------------------

Univariate analysis of 19 studies (3178 patients) explored the prognostic role of SUV~max~ for OS and demonstrated a combined HR of 2.54 (95%CI: 1.86--3.49, *P*\<0.00001, *I*^*2*^ = 86%) ([Fig 4A](#pone.0146195.g004){ref-type="fig"}). *I*^*2*^ was not statistically significant (17 studies, 2698 patients, *P* = 0.19, *I*^*2*^ = 23%) after the exclusion of two studies \[[@pone.0146195.ref034], [@pone.0146195.ref039]\] with an HR of 2.26 (95%CI: 1.94--2.64). Begg's test revealed no significant publication bias (*z* = 1.47, *P* = 0.141). Heterogeneity also existed (*I*^*2*^ = 68%, *P* = 0.002, HR = 1.52, 95%CI: 1.16--2.00) in adjusted analyses of SUV~max~ and OS rate (9 studies, 1467 patients) ([Fig 4B](#pone.0146195.g004){ref-type="fig"}). Exclusion of the report from Bille et al.\[[@pone.0146195.ref039]\] reduced this heterogeneity and led to a *P* value of 0.69 (8 studies, 1063 patients, *I*^*2*^ = 0%). A fixed-effect model revealed that the combined HR reached 1.64 (95%CI: 1.34--1.99).

![Forest plots of HR for deaths with SUV~max~ (A, unadjusted; B, adjusted), MTV (C, unadjusted; D, adjusted) and TLG (E, unadjusted; F, adjusted).\
The Chi^2^ test is a measurement of heterogeneity. *P*\<0.05 indicates significant heterogeneity. Squares = individual study point estimates. Horizontal lines = 95% CIs. Rhombus = summarized estimate and its 95%CI. Fixed: fixed effect model. Random: random effect model.](pone.0146195.g004){#pone.0146195.g004}

Larger MTV predicted poor OS in univariate and multivariate analyses. Significant disparities were determined in unadjusted (4 studies, 860 patients, HR 2.07, 95%CI: 1.16--3.69, *P* = 0.005, *I*^*2*^ = 77%) and adjusted analyses (3 studies, 679 patients, HR = 1.91, 95%CI: 1.13--3.22, *P* = 0.11, *I*^*2*^ = 55%) ([Fig 4C and 4D](#pone.0146195.g004){ref-type="fig"}). High TLG was associated with poor OS in univariate analysis (5 studies, 1108 patients) with a combined HR of 2.47 (95%CI: 1.38--4.43, *P* = 0.0006, *I*^*2*^ = 79%). Multivariate analysis of 3 studies with 836 patients also demonstrated a significant prognostic role of TLG for OS (HR 1.94, 95%CI: 1.12--3.33, *P* = 0.04, *I*^*2*^ = 69%) ([Fig 4E and 4F](#pone.0146195.g004){ref-type="fig"}).

Stratified Analyses of SUV~max~ {#sec015}
-------------------------------

[Table 3](#pone.0146195.t003){ref-type="table"} summarizes total and stratified results. The combined HRs of SUV~max~ for stage I in the sub-group analysis for DFS according to disease stage were 3.62 (95%CI: 2.72--4.81, *P* = 0.07, *I*^*2*^ = 41%) from univariate analysis and 3.35 (95%CI: 2.18--5.16, *P* = 0.46, *I*^*2*^ = 0%) from multivariate analysis. Publication bias existed (Z = 2.81, P = 0.005) in univariate analysis, and the pooled HR was 3.00 (95%CI: 2.30--3.91) after the trim and fill process ([Fig 3C](#pone.0146195.g003){ref-type="fig"}). The combined HRs of SUV~max~ from univariate analysis of stage I and stage II for OS were 3.43 (95%CI: 1.75--6.75, *P* = 0.01, *I*^*2*^ = 66%) and 2.64 (95%CI: 1.11--6.31, *P* = 0.23, *I*^*2*^ = 31%), respectively.

10.1371/journal.pone.0146195.t003

###### Total and subgroup analyses of SUV~max~, MTV and TLG in surgical NSCLC.
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  Endpoint   Parameter   Factor             Data source   No. of studies   HR     95%CI of HR   Heterogeneity, *I*^*2*^(%)   Model used
  ---------- ----------- ------------------ ------------- ---------------- ------ ------------- ---------------------------- ------------
  DFS        SUV~max~    Total              Unadjusted    22               2.74   2.33--3.24    32                           Fixed
                                            Adjusted      17               2.43   1.76--3.36    72                           Random
                         Stage I            Unadjusted    11               3.62   2.72--4.81    41                           Fixed
                                            Adjusted      6                3.35   2.18--5.16    0                            Fixed
                         ADC                Unadjusted    4                4.81   2.87--8.08    47                           Fixed
                                            Adjusted      4                2.92   1.19--7.17    77                           Random
                         Non-ADC            Unadjusted    3                1.98   1.04--3.79    0                            Fixed
                         Surgery only       Unadjusted    19               2.75   2.30--3.29    41                           Fixed
                                            Adjusted      15               2.30   1.65--3.20    72                           Random
                         Threshold ≤ 5.9    Unadjusted    14               3.02   2.42--3.77    46                           Fixed
                                            Adjusted      11               4.63   2.53--8.48    62                           Random
                         Threshold \> 5.9   Unadjusted    10               2.42   1.89--3.11    38                           Fixed
                                            Adjusted      7                1.68   1.07--2.63    58                           Random
             MTV         Total              Unadjusted    5                2.27   1.77--2.90    39                           Fixed
                                            Adjusted      4                2.49   1.23--5.04    63                           Random
             TLG         Total              Unadjusted    4                2.46   1.91--3.17    1                            Fixed
                                            Adjusted      3                2.97   1.68--5.28    59                           Random
  OS         SUV~max~    Total              Unadjusted    19               2.54   1.86--3.49    86                           Random
                                            Adjusted      9                1.52   1.16--2.00    68                           Random
                         Stage I            Unadjusted    6                3.43   1.75--6.75    66                           Random
                                            Adjusted      2                2.14   1.21--3.77    0                            Fixed
                         Stage II           Unadjusted    3                2.64   1.11--6.31    31                           Fixed
                         Surgery only       Unadjusted    16               2.27   1.93--2.66    48                           Fixed
                                            Adjusted      7                1.59   1.30--1.95    0                            Fixed
                         Threshold ≤ 5.9    Unadjusted    8                3.47   2.10--5.71    68                           Random
                                            Adjusted      3                1.61   1.22--2.12    0                            Fixed
                         Threshold \> 5.9   Unadjusted    10               2.12   1.44--3.13    85                           Random
                                            Adjusted      5                1.42   0.97--2.08    67                           Random
             MTV         Total              Unadjusted    4                2.07   1.16--3.69    77                           Random
                                            Adjusted      3                1.91   1.13--3.22    55                           Random
             TLG         Total              Unadjusted    5                2.47   1.38--4.43    79                           Random
                                            Adjusted      3                1.94   1.12--3.33    69                           Random

**Abbreviations:** SUV~max~: maximal standardized uptake value; MTV: metabolic tumor volume; TLG: total lesion glycolysis; NSCLC: non-small cell lung cancer; HR: hazard ratio; CI: confidence interval; DFS: disease-free survival; OS: overall survival; ADC: adenocarcinoma.

Sub-group analysis based on the histology type revealed that the combined HRs of SUV~max~ on DFS from univariate analysis for adenocarcinoma and non-adenocarcinoma were 4.81 (95%CI: 2.87--8.08, *P* = 0.13, *I*^*2*^ = 47%) and 1.98 (95%CI: 1.04--3.79, *P* = 0.64, *I*^*2*^ = 0%), respectively. Four studies provided multivariate analysis of SUV~max~ on DFS for adenocarcinoma patients, with a pooled HR of 2.92 (95%CI: 1.19--7.17, *P* = 0.005, *I*^*2*^ = 77%).

The combined HRs of SUV~max~ on DFS were 2.75 (95%CI: 2.30--3.29, *P* = 0.03, *I*^*2*^ = 41%) and 2.30 (95%CI: 1.65--3.20, *P*\<0.01, *I*^*2*^ = 72%) in unadjusted and adjusted analysis, respectively, when analyses were narrowed to surgical only patients without adjuvant therapy. The pooled HRs of SUV~max~ in univariate and multivariate analysis were 2.27 (95%CI: 1.93--2.66, *P* = 0.02, *I*^*2*^ = 48%) and 1.59 (95%CI: 1.30--1.95, *P* = 0.79, *I*^*2*^ = 0%), respectively, for OS.

Cut-off values of SUV~max~ in each individual study were determined to be high (\>5.9) or low (\< = 5.9) based on the median value. Subgroup analyses demonstrated that the combined HRs of SUV~max~ for high cut-off value were 2.42 (95%CI: 1.89--3.11, *P* = 0.10, *I*^*2*^ = 38%) from univariate analysis and 1.68 (95%CI: 1.07--2.63, *P* = 0.03, *I*^*2*^ = 58%) from multivariate analysis. The low cut-off value studies demonstrated that the combined HRs of SUV~max~ (univariate analysis: HR 3.02, 95%CI: 2.42--3.77, *P* = 0.03, *I*^*2*^ = 46%; multivariate analysis: HR 4.63, 95%CI: 2.53--8.48, *P* = 0.003, *I*^*2*^ = 62%) were larger than the high cut-off value subgroup. Analysis of OS data also revealed a similar trend with pooled HRs of 3.47 (95%CI: 2.10--5.71, *P* = 0.003, *I*^*2*^ = 68%) and 1.61 (95%CI: 1.22--2.12, *P* = 0.38, *I*^*2*^ = 0%) for high cut-off group and 2.12 (95%CI: 1.44--3.13, *P*\<0.01, *I*^*2*^ = 85%) and 1.42 (95%CI: 0.97--2.08, *P* = 0.02, *I*^*2*^ = 67%) for low cut-off group in unadjusted and adjusted analyses, respectively.

Discussion {#sec016}
==========

There is a high risk of local relapse and distant metastasis after curative resection for early-stage and localized NSCLC. Therefore, adjuvant therapy was explored to eliminate occult metastases and/or loco-regional residual tumor cells with a consequent reduction on recurrence and prolonged survival. It is essential to identify prognostic factors that may predict patients who are at a high risk of recurrence who will attain the most benefit from the adjuvant therapy to optimize the treatment. The evidence-based use of adjuvant therapy is highly dependent on clinical-pathological tumor staging information in the clinical setting. The role of ^18^F-FDG PET/CT imaging for the prediction of local control and OS in surgical NSCLC must be investigated because it may provide important biological information beyond TNM staging. The present systemic review and meta-analysis found that higher values of SUV~max~, MTV and TLG predicted a higher risk of disease recurrence or death in patients with surgical NSCLC. The positive association remained statistically significant across stratified analyses according to stage, pathology and cut-off values. FDG PET/CT may be used to select patients who are at high risk of tumor recurrence or death and may benefit from subsequent more aggressive treatments.

SUV~max~ is the most commonly used parameter in ^18^F-FDG PET/CT diagnosis and response monitoring because of high reproducibility and availability. The potential prognostic value of SUV~max~ for primary lung cancer was widely reported in various staged and treated populations \[[@pone.0146195.ref008]--[@pone.0146195.ref010], [@pone.0146195.ref014]\] ([Table 4](#pone.0146195.t004){ref-type="table"}). Therefore, our meta-analysis focused on surgical NSCLC only and provided the most comprehensive information for the total population and sub-groups based on disease stage, pathological classification and cut-off values. However, SUV~max~ only provides information about a single volumetric pixel within the tumor, and it does not measure the volume or heterogeneity of metabolically active disease. Volumetric parameters, such as MTV and TLG, were investigated recently. The prognostic role of MTV and TLG was meta-analyzed in NSCLC patients with different stages \[[@pone.0146195.ref011]\]. Similar results were derived in our study, which focused on surgical NSCLC patients. Volume-based parameters exhibit advantages in the measurement of metabolic tumor burden, but controversy on the most appropriate segmentation method to measure MTV and TLG remains. Potential preferable performance of volumetric parameters to SUV~max~ as prognostic factors were reported by the studies \[[@pone.0146195.ref024], [@pone.0146195.ref028], [@pone.0146195.ref029], [@pone.0146195.ref052], [@pone.0146195.ref053]\] that reported complete data of FDG PET/CT-derived parameters. The present meta-analysis demonstrated that SUV~max~ performed equally with volumetric parameters based on existing data because of the limited data of volumetric parameters compared with FDG uptake. Other FDG PET/CT imaging characteristics beyond traditional parameters were also studied, such as intratumor FDG uptake heterogeneity. This parameter, as an area under the curve (AUC) of the cumulative histogram, and texture analysis predict tumor control \[[@pone.0146195.ref059]\] and are independent prognostic factors for survival \[[@pone.0146195.ref060]--[@pone.0146195.ref062]\] in NSCLC. However, these reports were not included in present meta-analysis because the study population was relatively small.

10.1371/journal.pone.0146195.t004

###### Previous meta-analyses of 18F-FDG PET/CT on survival of NSCLC patients.

![](pone.0146195.t004){#pone.0146195.t004g}

  Study                                         Year   Stage   Treatment      No. of studies   No. of patients   Endpoints   PET parameters       HR (95% CI)
  --------------------------------------------- ------ ------- -------------- ---------------- ----------------- ----------- -------------------- ----------------------------------------------
  Na et al. \[[@pone.0146195.ref008]\]          2014   I-IV    Radiotherapy   13               1081              OS/LC       SUV~max~             OS: 1.05 (1.02--1.08) LC: 1.26 (1.05--1.52)
  Nair et al. \[[@pone.0146195.ref009]\]        2009   I       Surgery        9                1166              OS/DFS      SUV~max~/SUV~mean~   NA
  Paesmans et al. \[[@pone.0146195.ref010]\]    2010   I-IV    Any            24               2638              OS/DFS      SUV                  2.08 (1.69--2.56)
  Im et al. \[[@pone.0146195.ref011]\]          2014   I-IV    Any            13               1581              OS/EFS      MTV                  OS: 2.31 (1.54--3.47) EFS: 2.71 (1.82--4.02)
                                                                                                                             TLG                  OS: 2.43 (1.89--3.11) EFS: 2.35 (1.91--2.89)
  Berghmans et al. \[[@pone.0146195.ref014]\]   2008   I-IV    Any            13               1474              OS          SUV~max~             2.27 (1.70--3.02)

**Abbreviations:** FDG: fluorodeoxyglucose; PET/CT: positron emission tomography/computed tomography; NSCLC: non-small cell lung cancer; HR: hazard ratio; OS: overall survival; LC: local control; SUV~max~: maximal standardized uptake value; SUV~mean~: mean standardized uptake value; NA: not available; MTV: metabolic tumor volume; TLG: total lesion glycolysis; DFS: disease-free survival; EFS: event-free survival.

Patient heterogeneity, statistical data mining, retrospective cohorts, PET acquisition and calculations of SUV~max~ are significant contributors to heterogeneity, which limited the application of glucose uptake as a companion diagnostic/prognostic marker. NSCLC is a heterogeneous disease. Patients with different histological types, stages, surgical procedures and adjuvant treatments were included in the meta-analysis. For example, Higashi et al. \[[@pone.0146195.ref041]\] and Stiles et al. \[[@pone.0146195.ref044]\] applied similar thresholds for FDG uptake. Significant differences were found in Higashi's study in DFS (HR 8.17, 95%CI: 2.83--23.53), but statistically significant differences in DFS were not found in Stiles's study (HR 1.54, 95%CI: 0.92--2.56). There were more patients with stage I NSCLC (80.7% versus 76.8%) and more patients with bronchioloalveolar cell carcinoma (22.8% of BAC versus \<8.3%) in Higashi's study, which may explain the lower risk of recurrence in patients with low tumor FDG uptake. The heterogeneity in PET imaging thresholds was also obvious between the studies, which be explained by many factors, including the type of PET machine, the algorithms for iteration and reconstruction, the time elapsed between FDG injection and emission scan, and the method for threshold determination. Differences in defining the regions of interest \[[@pone.0146195.ref063]\] and timing of the data acquisition \[[@pone.0146195.ref064]\] may also result in different absolute SUV estimates.

Heterogeneity between the included reports was the main limitation of this meta-analysis. Non-English articles were excluded. The fact that small sample studies with negative results are less frequently published or published with simple descriptions led to the phenomenon of increased standard error for higher HRs. The trim and fill sensitivity analysis in the present study, which incorporates the hypothetical missing studies, did not change the general result, which suggests that the association was convincible. Individual HRs from small sample studies weighed less in the total HR, and it was also helpful to ensure the reliability of results. MTV and TLG were measured in 7 studies only. Multivariate analyses were based on 5 studies for MTV and 4 for TLG. Too little data were available to meta-analyze the values of volumetric PET/CT parameters for the prediction of patient's prognosis. Only 2 included studies were prospectively designed, but PET as a biomarker to prognosticate or predict the response to therapy was assessed over 10 years. The prospectively designed studies \[[@pone.0146195.ref065], [@pone.0146195.ref066]\] that were ineligible for the present meta-analysis also reported primarily positive results on various FDG PET/CT-derived parameters of lung cancer patients. Our meta-analysis offers a considerably valid conclusion for clinical practice under the circumstance of insufficient evidence from prospectively designed data.

In summary, this meta-analysis demonstrated that high values of SUV~max~ and MTV derived from the pretreatment of ^18^F-FDG PET/CT predicted a higher risk of recurrence or death in surgical NSCLC patients. Our findings suggest that FDG PET/CT may be used for risk stratification in disease control and survival. Patients with tumors who exhibit intense FDG uptake may be considered at a high risk of treatment failure and may benefit from more aggressive treatment. Further individual patient data should be meta-analyzed to determine the optimal threshold for PET imaging parameters.
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